Market Overview:
The global 5-hydroxytryptamine receptor 7 market is expected to register a CAGR of xx% during the forecast period 2018-2030. The market growth can be attributed to the increasing prevalence of psychiatric disorders, such as schizophrenia, autism, psychosis, and major depressive disorder. Additionally, the increasing R&D investments for novel drug therapies are also propelling the growth of this market. However, stringent regulatory approvals and high development costs are restraining the growth of this market. Based on type, JNJ-18038683 is expected to account for a major share in the global 5-hydroxytryptamine receptor 7 market during 2018-2030. This can be attributed to its high efficacy in treating various psychiatric disorders. Based on application, schizophrenia is estimated to account for a majority share in 2018 and it is projected that this trend will continue during the forecast period.
Product Definition:
5-Hydroxytryptamine Receptor 7 (5-HT7) is a G protein-coupled receptor that in humans is encoded by the HTR7 gene. The 5-HT7 receptor is a member of the family of serotonin receptors, which are G protein coupled receptors (GPCRs) that stimulate intracellular signaling cascades upon activation by their ligands.
JNJ-18038683:
Joint compound (JPC) is a drug combination used in the treatment of rheumatoid arthritis. It is a combination of two drugs, called TNF alpha inhibitor and DMARD. The first one is called TNF alpha inhibitor and it stops the inflammatory process that leads to pain in case of rheumatoid arthritis by blocking cytokines such as tumor necrosis factor-alpha (TNF-alfa).
ATI-9242:
ATI-9242 is a selective 5-HT1A receptor agonist developed by Arena Pharmaceuticals. It was granted Fast Track designation as the Most Potent New Drug by the U.S. FDA in 2015, and has been approved for treating Social Anxiety Disorder (SAD) in 2016.
Application Insights:
The other applications segment includes anxiety, sleep disorders and others. The major depressive disorder order segment dominated the overall market in terms of revenue share in 2017. This is due to the high prevalence of depression coupled with increasing awareness about effective treatment options such as 5-HT3 receptor partial agonist compounds for major depressive disorder.
Furthermore, there are a number of product candidates under clinical trials stage for various indications such as schizophrenia, anxiety disorders and insomnia that are expected to contribute significantly towards market growth over the forecast period. For instance, ADN-3662 being a 5-hydroxytryptamine (5-HT) 3 receptor partial agonist is currently in phase 3 of clinical trial for treating schizophrenia which is anticipated to result in substantial product demand during the forecast period.
Moreover, JNJ Corporation has applied for U.S.
Regional Analysis:
North America dominated the global 5-hydroxytryptamine receptor 7 market in 2017. The region is expected to continue its dominance over the forecast period as well, owing to increasing R&D investments and high adoption ofserotonin reuptake inhibitors (SSRIs) for treating mental disorders. Asia Pacific is expected to grow at a lucrative rate during the forecast period due to rising disposable income and improving healthcare infrastructure in emerging countries such as India and China. Moreover, an increase in awareness aboutserotonin deficiency syndrome among physicians & patients will drive regional growth further.
Europe was estimated be USD X million in 2017 owing to presence of developed economies such as U.K., Germany along with other emerging nations including Russia & Poland that are major consumers of serotonergic drugs worldwide (Volkow et al., 2015).
Growth Factors:
- Increasing research and development activities by pharmaceutical companies for the development of novel drugs to treat various diseases
- Rising prevalence of neurological disorders such as depression, anxiety, and insomnia
- Growing demand for 5-HT7 receptor agonists in the treatment of cardiovascular diseases
- increasing geriatric population susceptible to neurological and psychiatric disorders
- Technological advancements in drug discovery and development processes
Scope Of The Report
Report Attributes
Report Details
Report Title
5-Hydroxytryptamine Receptor 7 Market Research Report
By Type
JNJ-18038683, ATI-9242, ADN-3662, RP-5063, Others
By Application
Schizophrenia, Autism, Psychosis, Major Depressive Diorder, Others
By Companies
Adamed Sp z oo, Astellas Pharma Inc, Braeburn Pharmaceuticals Inc, H. Lundbeck A/S, Johnson & Johnson, Reviva Pharmaceuticals Inc, Sumitomo Dainippon Pharma Co Ltd, Adamed Sp z oo
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
125
Number of Tables & Figures
88
Customization Available
Yes, the report can be customized as per your need.
Global 5-Hydroxytryptamine Receptor 7 Market Report Segments:
The global 5-Hydroxytryptamine Receptor 7 market is segmented on the basis of:
Types
JNJ-18038683, ATI-9242, ADN-3662, RP-5063, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Schizophrenia, Autism, Psychosis, Major Depressive Diorder, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Adamed Sp z oo
- Astellas Pharma Inc
- Braeburn Pharmaceuticals Inc
- H. Lundbeck A/S
- Johnson & Johnson
- Reviva Pharmaceuticals Inc
- Sumitomo Dainippon Pharma Co Ltd
- Adamed Sp z oo
Highlights of The 5-Hydroxytryptamine Receptor 7 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- JNJ-18038683
- ATI-9242
- ADN-3662
- RP-5063
- Others
- By Application:
- Schizophrenia
- Autism
- Psychosis
- Major Depressive Diorder
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the 5-Hydroxytryptamine Receptor 7 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
5-Hydroxytryptamine receptor 7 is a protein that in humans is encoded by the HTRA7 gene. 5-HT receptors are G protein-coupled receptors that are widely distributed in the brain and spinal cord, where they play roles in neuropsychiatric disorders such as anxiety, depression, addiction and obsessive–compulsive disorder.
Some of the major companies in the 5-hydroxytryptamine receptor 7 market are Adamed Sp z oo, Astellas Pharma Inc, Braeburn Pharmaceuticals Inc, H. Lundbeck A/S, Johnson & Johnson, Reviva Pharmaceuticals Inc, Sumitomo Dainippon Pharma Co Ltd, Adamed Sp z oo.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 5-Hydroxytryptamine Receptor 7 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 5-Hydroxytryptamine Receptor 7 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 5-Hydroxytryptamine Receptor 7 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the 5-Hydroxytryptamine Receptor 7 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global 5-Hydroxytryptamine Receptor 7 Market Size & Forecast, 2020-2028
4.5.1 5-Hydroxytryptamine Receptor 7 Market Size and Y-o-Y Growth
4.5.2 5-Hydroxytryptamine Receptor 7 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 JNJ-18038683
5.2.2 ATI-9242
5.2.3 ADN-3662
5.2.4 RP-5063
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Schizophrenia
6.2.2 Autism
6.2.3 Psychosis
6.2.4 Major Depressive Diorder
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global 5-Hydroxytryptamine Receptor 7 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 5-Hydroxytryptamine Receptor 7 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 JNJ-18038683
9.6.2 ATI-9242
9.6.3 ADN-3662
9.6.4 RP-5063
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Schizophrenia
9.10.2 Autism
9.10.3 Psychosis
9.10.4 Major Depressive Diorder
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 JNJ-18038683
10.6.2 ATI-9242
10.6.3 ADN-3662
10.6.4 RP-5063
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Schizophrenia
10.10.2 Autism
10.10.3 Psychosis
10.10.4 Major Depressive Diorder
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 JNJ-18038683
11.6.2 ATI-9242
11.6.3 ADN-3662
11.6.4 RP-5063
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Schizophrenia
11.10.2 Autism
11.10.3 Psychosis
11.10.4 Major Depressive Diorder
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 JNJ-18038683
12.6.2 ATI-9242
12.6.3 ADN-3662
12.6.4 RP-5063
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Schizophrenia
12.10.2 Autism
12.10.3 Psychosis
12.10.4 Major Depressive Diorder
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 JNJ-18038683
13.6.2 ATI-9242
13.6.3 ADN-3662
13.6.4 RP-5063
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Schizophrenia
13.10.2 Autism
13.10.3 Psychosis
13.10.4 Major Depressive Diorder
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 5-Hydroxytryptamine Receptor 7 Market: Competitive Dashboard
14.2 Global 5-Hydroxytryptamine Receptor 7 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Adamed Sp z oo
14.3.2 Astellas Pharma Inc
14.3.3 Braeburn Pharmaceuticals Inc
14.3.4 H. Lundbeck A/S
14.3.5 Johnson & Johnson
14.3.6 Reviva Pharmaceuticals Inc
14.3.7 Sumitomo Dainippon Pharma Co Ltd
14.3.8 Adamed Sp z oo
